13266
In a randomized , nonblind , phase III study , subcutaneous bortezomib was noninferior to intravenous bortezomib in the treatment of adults with relapsed multiple myeloma , as determined by the overall response rate after four cycles of therapy ( primary endpoint ) .
 Chemical: bortezomib; Chemical: bortezomib
Please list all entity words in the text that fit the category.Output format is "type1: word1; type2: word2". 
Option: Chemical 
Text: {0} 
Answer:
 Chemical: bortezomib; Chemical: bortezomib